148 related articles for article (PubMed ID: 17015999)
1. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.
Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S
Intern Med; 2006; 45(17):995-9. PubMed ID: 17015999
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
[TBL] [Abstract][Full Text] [Related]
3. A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia.
Seki M; Higashiyama Y; Imamura Y; Nakamura S; Kurihara S; Izumikawa K; Kakeya H; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
Intern Med; 2009; 48(1):49-55. PubMed ID: 19122356
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
[TBL] [Abstract][Full Text] [Related]
6. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
Okimoto N; Kurihara T; Honda N; Asaoka N; Fujita K; Ohba H; Nakamura J
J Infect Chemother; 2003 Jun; 9(2):183-6. PubMed ID: 12825120
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
Wood GC; Hanes SD; Croce MA; Fabian TC; Boucher BA
Clin Infect Dis; 2002 Jun; 34(11):1425-30. PubMed ID: 12015687
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Jellison TK; Mckinnon PS; Rybak MJ
Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
[TBL] [Abstract][Full Text] [Related]
9. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
10. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
[TBL] [Abstract][Full Text] [Related]
11. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
12. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.
Ito I; Kadowaki S; Tanabe N; Haruna A; Kase M; Yasutomo Y; Tsukino M; Nakai A; Matsumoto H; Niimi A; Chin K; Ichiyama S; Mishima M
Pulm Pharmacol Ther; 2010 Oct; 23(5):403-10. PubMed ID: 20561917
[TBL] [Abstract][Full Text] [Related]
13. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime.
Ho A; Leung R; Lai CK; Chan TH; Chan CH
Respiration; 1997; 64(3):224-8. PubMed ID: 9154675
[TBL] [Abstract][Full Text] [Related]
14. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
Grayson ML; Gibbons GW; Habershaw GM; Freeman DV; Pomposelli FB; Rosenblum BI; Levin E; Karchmer AW
Clin Infect Dis; 1994 May; 18(5):683-93. PubMed ID: 8075257
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.
Williams D; Perri M; Zervos MJ
Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):293-8. PubMed ID: 8070432
[TBL] [Abstract][Full Text] [Related]
16. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
[TBL] [Abstract][Full Text] [Related]
20. [A community acquired pneumonia case caused by Ralstonia pickettii].
Küçükbayrak A; Uğurman F; Dereli N; Cizmeci Z; Günay E
Mikrobiyol Bul; 2009 Apr; 43(2):331-4. PubMed ID: 19621622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
